Physician profile
Lorri J Darrow
NPI 1679579593
$47,202.40
in general payments reported to CMS, 2019-2025
29 companies · $28K in 2025
The $28K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.27 · 2020: $121 · 2021: $602 · 2022: $960 · 2023: $1,813 · 2024: $16K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Food and Beverage: $7,746 · Travel and Lodging: $1,385 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,238.00 |
| Food and Beverage | $7,746.09 |
| Travel and Lodging | $1,385.12 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $39,362.29 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,199.27 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,043.66 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $758.95 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $751.40 | 2023-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $615.56 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $529.20 | 2023-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $437.06 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $422.25 | 2023-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $419.55 | 2023-2025 | Auvelity |
| Lundbeck LLC | $255.91 | 2020-2025 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $250.12 | 2022-2025 | Rejoyn, Abilify Asimtufii, Rexulti |
| Napo Pharmaceuticals INC | $229.22 | 2023-2025 | Mytesi |
| E.R. Squibb & Sons, L.L.C. | $190.04 | 2025 | Cobenfy |
| Viiv Healthcare Company | $130.90 | 2022-2025 | Cabenuva, Apretude, Rukobia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $129.58 | 2023 | Symtuza |
| Gilead Sciences, INC. | $90.37 | 2021 | |
| Emd Serono, INC. | $85.81 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.23 | 2021-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $58.33 | 2021-2024 | Pifeltro, Dificid, Delstrigo |
| Allergan, INC. | $29.99 | 2020 | |
| Lilly USA, LLC | $22.29 | 2024 | Mounjaro, Zepbound |
| Dexcom, INC. | $20.48 | 2025 | Dexcom G6 Transmitter |
| Neuronetics, INC. | $16.52 | 2021 | |
| Exact Sciences Corporation | $16.27 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.97 | 2025 | Xifaxan |
| Verona Pharma, INC. | $13.64 | 2025 | Ohtuvayre |
| Organon LLC | $13.57 | 2025 | Nexplanon |
| Novo Nordisk INC | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorri Darrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.